LIPO - Cash Flow Statement - Lipella Pharmaceuticals Inc.

Millions

	Dec-2024	Dec-2023	Dec-2022	Dec-2021	Dec-2020	Dec-2019
OPERATING CASH FLOW
Net Income	(5.0)	(4.6)	(2.6)	(1.9)	61.7 K	61.8 K
Depreciation & Amortization	2.89 K	1.68 K	0	0	0	0
Deferred Income Tax	0	0	0	0	0	0
Stock Based Compensation	0.7	1.4	0.7	0.7	57.7 K	0
Other Operating Activities	0.2	0.1	9.61 K	50.2 K	7.64 K	18.7 K
Change in Working Capital	0.1	9.11 K	9.52 K	0.2	32.3 K	14.3 K
Cash From Operations	(4.0)	(3.2)	(1.8)	(1.0)	28.6 K	39.1 K
INVESTING CASH FLOW
Capital Expenditures	0	14.4 K	0	0	0	0
Other Items	0	0	0.3	(0.3)	0	0
Cash From Investing Activities	0	14.4 K	0.3	(0.3)	0	0
FINANCING CASH FLOW
Common Stock Repurchased	0	0	0	0	0	0
Total Debt Repaid	0	(0.3)	0.3	0	57 K	25 K
Dividends Paid	0	0	0	0	0	0
Other Financing Activities	2.8	1.6	0	0	0	0
Cash From Financing Activities	2.8	1.3	5.2	2.1	0.6	25 K
CHANGE IN CASH
Net Change In Cash	(1.1)	(1.8)	3.7	0.8	0.6	14.1 K
FREE CASH FLOW
Free Cash Flow	(4.0)	(3.2)	(1.8)	(1.0)	28.6 K	39.1 K

Free